SCHEMBL17492162

SCHEMBL17492162

CC(C)(C)OC(=O)NC(COc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 9/20 0.50
▸ PPARG P37231 8/20 0.50
▸ SCN9A Q15858 4/20 0.47
▸ ITGB3 P05106 1/20 0.44
▸ ITGA2B P08514 1/20 0.44
▸ ACE P12821 2/20 0.44
▸ PTPN1 P18031 1/20 0.43
▸ PPARD Q03181 2/20 0.41
▸ CTSS P25774 1/20 0.40
▸ MME P08473 1/20 0.39
▸ CPA1 P15085 1/20 0.39
▸ ACE2 Q9BYF1 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39
▸ APH1A Q96BI3 1/20 0.39
▸ PSENEN Q9NZ42 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17492160 1.00 PPARA (0.50) PPARAPPARGSCN9AITGB3ITGA2B
SCHEMBL19105156 0.93 PPARA (0.47) PPARAPPARGSCN9AITGB3ITGA2B
SCHEMBL17492077 0.89 SCN9A (0.46) PPARAPPARGSCN9AITGB3ITGA2B
SCHEMBL17492075 0.89 SCN9A (0.46) PPARAPPARGSCN9AITGB3ITGA2B
SCHEMBL16384487 0.88 PPARA (0.58) PPARAPPARGITGB3ITGA2BACE
SCHEMBL4024742 0.83 PPARA (0.63) PPARAPPARGACECTSSMME
SCHEMBL17491971 0.82 GRN (0.54) PPARAPPARGITGB3ITGA2BACE
SCHEMBL17491974 0.82 GRN (0.54) PPARAPPARGITGB3ITGA2BACE
SCHEMBL18750485 0.81 SCN9A (0.66) SCN9ACTSS
SCHEMBL4818304 0.80 PPARA (0.62) PPARAPPARGSCN9AITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106459147-B Serine derivatives as ghrelin receptor agonists 拉夸里亚创药株式会社 2021-08-06 — — CN disclosed
EP-3131916-B1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC (JP) 2018-11-14 — — EP disclosed
US-9873695-B2 Serine derivatives as ghrelin receptor agonists RAQUALIA PHARMA INC. (JP) 2018-01-23 — — US disclosed
US-20170197961-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC. (JP) 2017-07-13 — — US disclosed
EP-3131916-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RaQualia Pharma Inc (JP) 2017-02-22 — — EP disclosed
WO-2016021191-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS RAQUALIA PHARMA INC. (JP) 2016-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197961-A1 SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS GHSR, GHRHR, GIPR PPARA 911/4885PPARG 345/4885SCN9A 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback